Latest News

In the last hour
AbbVie (ABBV) Rises Higher Than Market: Key Facts Zacks23:51 12-Jun-26
Yesterday
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend. The Motley Fool11:38 12-Jun-26
AbbVie Reports Nine-Year Venetoclax Data In First-Line CLL RTT News09:48 12-Jun-26
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic… AbbVie (Press Release)08:07 12-Jun-26
AbbVie Loses Colorado 340B Drug Pricing Law Challenge Law36001:43 12-Jun-26
In the last 7 days
Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026? Zacks17:33 11-Jun-26
AbbVie, Devon Energy And More On CNBC's 'Final Trades' Benzinga13:00 11-Jun-26
NICE recommends AbbVie’s migraine treatment Pharmaceutical Field10:48 11-Jun-26
Aquipta recommended by NICE for acute migraine treatment PharmaTimes14:45 10-Jun-26
Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations… AbbVie (Press Release)13:02 10-Jun-26
AbbVie's migraine drug cleared for migraine attacks on NHS pharmaphorum11:57 10-Jun-26
AbbVie’s Skyrizi narrowly slides ahead of J&J’s Tremfya in May drug ad spending rankings FiercePharma07:30 10-Jun-26
Novartis, AbbVie Lose Bid To Halt Wash. 340B Pharmacy Law Law36004:04 10-Jun-26
Should You Buy, Sell or Hold ABBV Stock After It Rises 12% in a Month? Zacks18:21 8-Jun-26
Camargo v. AbbVie, Inc. U.S. Chamber of Commerce (Press Release)15:10 8-Jun-26
AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 AbbVie (Press Release)13:01 8-Jun-26
AbbVie, UnitedHealth, Sabra Health Care And A Consumer Defensive Stock On CNBC's 'Final Trades' Benzinga12:49 8-Jun-26
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? The Motley Fool07:05 8-Jun-26
Assessing AbbVie (ABBV) Valuation After Fresh Regulatory Wins In Migraine And Blood Cancer Simply Wall St14:22 6-Jun-26
In the last month
AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note Zacks23:53 5-Jun-26
AbbVie, Oracle, Apple And More On CNBC's 'Final Trades' Benzinga13:32 5-Jun-26
AbbVie Loses Latest Challenge Against Mississippi Pharmacy Law Bloomberg Law17:20 4-Jun-26
Generalized Anxiety Disorder Market Forecast Shows Strong CAGR During the Forecast Period… PR Newswire (Press Release)15:03 4-Jun-26
First new NHS treatment in over 20 years recommended for women with resistant ovarian cancer Clinical Services Journal14:55 4-Jun-26
AbbVie Appoints Kelly Sanderson Schrems as UK Vice President and General Manager Pharmaceutical Field12:42 4-Jun-26
AbbVie's ovarian cancer drug Elahere gets NHS green light pharmaphorum09:02 4-Jun-26
AbbVie Loses Miss. Discount Drug Law Challenge For Good Law36004:42 4-Jun-26
British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy The Tribune, California00:21 4-Jun-26
AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine Zacks16:11 3-Jun-26
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know Zacks15:00 3-Jun-26
AbbVie receives EC approval for Aquipta to treat migraine Pharmaceutical Technology10:40 3-Jun-26
Johnson & Johnson Hopes to Dethrone AbbVie's Biggest Growth Driver. Here's Why Investors Shouldn't Panic The Motley Fool19:58 2-Jun-26
AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference AbbVie (Press Release)13:02 2-Jun-26
AbbVie Announces European Commission Approval of Aquipta® (atogepant) for the Acute Treatment… PR Newswire (Press Release)09:06 2-Jun-26
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? The Motley Fool19:43 1-Jun-26
AbbVie, Pfizer win broader reimbursement for oral JAK inhibitors in Korea Korea Biomedical Review03:11 1-Jun-26
Regulatory tracker: J&J grows Tremfya label stateside; AbbVie nets EU Venclyxto expansion FiercePharma17:35 29-May-26
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector? Barchart14:45 29-May-26
AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional… AbbVie (Press Release)13:02 29-May-26
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo Pharmaceutical Technology07:44 29-May-26
AbbVie’s ImmunoGen Deal Bears More Fruit With Decnupaz Approval Scrip Pharma Intelligence22:05 28-May-26
Elzonris this: FDA clears Abbvie’s Decnupaz in Bpdcn BioWorld21:37 28-May-26
AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication Zacks16:15 28-May-26
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset FiercePharma12:35 28-May-26
AbbVie's Immunogen buy delivers rare cancer drug approval pharmaphorum10:14 28-May-26
AbbVie’s Elahere clears 1st reimbursement hurdle for platinum-resistant ovarian cancer in Korea Korea Biomedical Review02:09 28-May-26
FDA approves AbbVie's rare blood cancer drug The Tribune, California23:38 27-May-26
U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid… AbbVie (Press Release)23:22 27-May-26
US FDA approves AbbVie's rare blood cancer drug The Tribune, California20:56 27-May-26
How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds? Zacks18:30 27-May-26
Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF… PR Newswire (Press Release)13:36 27-May-26
Goldman Sachs, Deckers Outdoor And A Health Care Stock: CNBC's 'Final Trades' Benzinga12:53 27-May-26
GE Vernova, Estée Lauder, A Health Care Stock And More On CNBC's 'Final Trades' Benzinga12:40 26-May-26
The innovation trap: How pharma weaponizes a word to extend monopolies STAT09:36 26-May-26
What's the Better Dividend Stock Today: AbbVie or Pfizer? The Motley Fool17:33 24-May-26
AbbVie, GSK race up patient reputation leaderboard in the UK FiercePharma18:33 22-May-26
AbbVie plots 85 summer layoffs tied to Allergan aesthetics unit in California FiercePharma17:22 22-May-26
Novartis, AbbVie plan summer layoffs on opposite coasts FiercePharma16:31 22-May-26
AbbVie Announces Positive Chmp Opinion for Maviret® (glecaprevir/pibrentasvir) for the… PR Newswire (Press Release)13:03 22-May-26
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market The Motley Fool10:17 22-May-26
AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its… PR Newswire (Press Release)23:47 21-May-26
Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the… FiercePharma14:04 21-May-26
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock Zacks15:10 19-May-26
Ill. Panel Sides With AbbVie In Eye-Stent Injury Suit Law36000:26 19-May-26
AbbVie Leverages Successes And Setbacks To Grow In Neuroscience Scrip Pharma Intelligence23:25 18-May-26
AbbVie loses patent plea for Hep C drug The Times of India20:31 18-May-26
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth Zacks18:24 18-May-26
Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie? Zacks18:44 15-May-26
See Which Recent 13F Filers Hold ABBV But Odyssean and Neo Ivy Capital Management Exited Nasdaq18:25 15-May-26
How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results? Zacks17:02 15-May-26
BeiGene Must Face AbbVie's Chemical Trade Secret Claims Law36022:20 14-May-26
BeiGene Can’t Toss AbbVie Trade Secrets Suit Over Cancer Therapy Bloomberg Law00:02 14-May-26
The Zacks Analyst Blog NVIDIA, Mastercard, AbbVie, Waterstone and Precipio Zacks12:19 13-May-26

      
            
      
    view more headlines
   
      
      
      
12 Jun 23:51
   

AbbVie News

NewsNow aims to be the world's most accurate and comprehensive aggregator of AbbVie news, covering the latest share price, company announcements, vaccine trials, product news and more from the best online publications. Every story from every site is brought to you automatically and continuously 24/7, within around 10 minutes of publication.

AbbVie

Latest News

AbbVie News

Biotech Top Stories

UK Top Stories

World Top Stories